Neurologic manifestations associated with COVID-19: a multicentre registry
Elodie Meppiel(Centre Hospitalier Saint-Denis), Thibault Fraisse, Peggy Perrin(Hôpitaux Universitaires de Strasbourg), Geoffroy Hautecloque-Raysz(Université Claude Bernard Lyon 1), T. de Broucker(School of the Art Institute of Chicago), Lucas Gorza(Hopitaux Civils de Colmar), Guillaume Baille, François SellaI(Hopitaux Civils de Colmar), Laure Bottin, J. Chauffier, Alexandra Bizot, N. Alloussi, Chloé De Broucker(Centre Hospitalier Saint-Denis), Luc Defebvre(Sorbonne Université), Paul Petitgas(Hopitaux Civils de Colmar), Nathan Peiffer‐Smadja(Université Claude Bernard Lyon 1), Joséphine Amevigbe, Céline Derollez(Sorbonne Université), Lydie Dubuc, Sophie Landré(Université Claude Bernard Lyon 1), Guillaume Béraud(Centre Hospitalier Saint-Denis), Thibault Allou, Mathilde Devaux, Lamia Bencherif, Solène Moulin(Inserm), Pierre Tattevin(Inserm), Jean-Philippe Csajaghy(Centre Hospitalier Saint-Denis), Cécile Descotes-Genon(Université Claude Bernard Lyon 1), Andréa Fickl, Hanifa Amarguellay, Elodie Dembloque, Alexandra Maury(Centre Hospitalier Saint-Denis), Nathalie Derache, Fabrice Bruneel(Herlev Hospital), Mathilde Barbaz(Centre Hospitalier de Versailles), Fanny Alby‐Laurent, Samia Bensaadi, Olivier Dereeper, Sophie Abgrall, Jean‐Philippe Camdessanché, Gilles Edan, Virginie Desestret(Centre Léon Bérard)
Cited by 142
Related Papers
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
|Clinical Microbiology and Infection|2021|945
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
|Neurology Neuroimmunology & Neuroinflammation|2021|702
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study
|The Lancet Neurology|2022|651
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Polymorphonuclear leukocytes mediate <i>Staphylococcus aureus</i> Panton-Valentine leukocidin-induced lung inflammation and injury
|Proceedings of the National Academy of Sciences|2010|335